Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma

Acta Pharmacologica Sinica

Volumn 26, Issue 5, 2005, Pages 629-634

  Yi, Cheng ^a   Huang, Ying ^b   Guo, Zhi Ying ^b   Wang, Shu Ren ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Bifidobacterium infantis; Cytosine deaminase; Gene therapy

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; NUCLEIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIFIDOBACTERIUM LONGUM INFANTIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; FEMALE; GENE INSERTION; GENE SEQUENCE; GENETIC TRANSFECTION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID GEX 1LAMBDA T; RECOMBINANT PLASMID; SEQUENCE ANALYSIS; SUICIDE GENE THERAPY; SUPERNATANT;

ANIMALS; BIFIDOBACTERIUM; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PLASMIDS; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 18844382645     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00094.x     Document Type: Article

References (17)

1. Miller CR, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, et al. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Anal Biochem 2002; 30: 189-99.
2. Miyagi T, Koshida K, Hori O, Konaka H, Katoh H, Kitagawa Y, et al. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med 2003; 5: 30-7.
3. Plumb JA, Bilsland A, Kakani R, Zhao J, Glasspool RM, Knox RJ, et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001; 20: 7797-803.
4. Brown NL, Lemoine NR. Clinical trials with GDEPT: cytosine deaminase and 5-fluorocytosine. Methods Mol Med 2004; 90: 451-7.
5. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001; 7: 3314-24.
6. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem 2001; 36: 577-95.
7. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002; 9: 291-6.
8. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anne J. Clostridium spores for tumor-specific drug delivery. Anticancer Drugs 2002; 13: 115-25.
9. Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 2000; 7: 269-74.
10. Wu Y, Yi C, Wang S, Zhang M, Zhang J. Investigation on tumor-targeting characteristics of Bifidobacterium infantis toward melanoma in mice. J Sichuan Univ 2003; 34: 435-8.
11. Vaupel PW. Oxygenation of solid tumors in drug resistance in oncology. In: Teicher BA, editor. New York: Marcel Dekker; 1993, P53-85.
12. Nagy H, Panis Y, Fabre M, Perrin H, Klatzmann D, Houssin D. Are hepatomas a good target for suicide gene therapy? An experimental study in rats using retroviral-mediated transfer of thymidine kinase gene. Surgery 1998; 123: 19-24.
13. Fujimori M, Amano J, Taniguchi S. The genus Bifidobacterium for cancer gene therapy. Curr Opin Drug Discov Devel 2002; 5: 200-3.
14. Yazawa K, Fujimoii M, Nakamura T, Sasaki T, Amano J, Kano Y, et al. Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 2001; 66: 165-70.
15. Nakamura T, Sasaki T, Fujimori M, Yazawa K, Kano Y, Amano J, et al. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci Biotechnol Biochem 2002; 66: 2362-6.
16. Kim TB, Song SH, Kang SC, Oh DK. Quantitative comparison of lactose and glucose utilization in Bifidobacterium longum cultures. Biotechnol Prog 2003; 19: 672-5.
17. Makelainen H, Tahvonen R, Salminen S, Ouwehand AC. In vivo safety assessment of two Bifidobacterium longum strains. Microbiol Immunol 2003; 47: 911-4.